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Abstract 29 
 30 
Loss of function mutations of the type 2 vasopressin receptor (V2R) in kidney can lead to 31 
nephrogenic diabetes insipidus (NDI). We studied a previously described, but uncharacterized 32 
mutation of V2R (N321K missense mutation) of an NDI patient. The properties of the mutant 33 
receptor were evaluated. We constructed a highly sensitive Epac based BRET 34 
(bioluminescence resonance energy transfer) biosensor to perform real-time cAMP 35 
measurements after agonist stimulation of transiently transfected HEK293 cells with V2Rs. β-36 
arrestin binding of the activated receptors was examined with luciferase-tagged β-arrestin and 37 
mVenus-tagged V2Rs using BRET technique. Cell surface expressions of HA-tagged 38 
receptors were determined with flow cytometry using anti-HA-Alexa488 antibodies. Cellular 39 
localization examinations were implemented with fluorescent tagged receptors visualized with 40 
confocal laser-scanning microscopy. The effect of various vasopressin analogues on V1R was 41 
tested on mouse arteries by wire myography. N321K mutant V2R showed normal cell surface 42 
expression but the potency of AVP for cAMP generation was low, while the clinically used 43 
desmopressin (dDAVP) was not efficient. The β-arrestin binding and internalization 44 
properties of the mutant receptor were also different compared to the wild type. Function of 45 
the mutant receptor can be rescued with administration of V2R receptor agonist dVDAVP, 46 
which had no detectable side effects on V1R in the effective cAMP generating concentrations. 47 
Based on the findings we could propose a therapeutical strategy for NDI patients carrying the 48 
N321K mutation, since our in vivo experiments suggest that dVDAVP could rescue the 49 
function of the N321K-V2R without significant side effect on V1R. 50 
 51 
 52 
Introduction 53 
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Members of the G protein-coupled receptor (GPCR) superfamily are a major group of cell 54 
surface receptors, which recognize hormones, neurotransmitters and sensory information, thus 55 
they play essential roles in physiological processes (1). In addition to their physiological 56 
importance, the pathological significance of GPCRs cannot be emphasized enough since at 57 
least 40% of the modern therapeutic drugs target directly or indirectly these receptors and 58 
their signaling (2). Mutations of GPCRs are responsible for numerous human diseases and 59 
more than 600 loss of function mutations of GPCR’s have been identified (3). Investigation of 60 
these mutations helps to reveal the functions and structures of the different GPCRs, moreover 61 
it may provide clues to find drugs targeting receptors (4). One of the most extensively 62 
investigated receptor regarding inactivating mutations is the type 2 vasopressin receptor 63 
(V2R). Loss of function mutations of V2R can cause nephrogenic diabetes insipidus (NDI) 64 
with different mechanisms (5,6). 65 
V2Rs are localized to the basolateral plasma membrane of the principal cells in the 66 
kidney collecting ducts and have essential roles in mediating the water-conserving effect of 67 
arginine-vasopressin (AVP). AVP is secreted from the neurohypohysis in response to 68 
increased plasma osmolality, and its effect on water reabsorption is mediated by V2R. 69 
Binding of AVP to V2R, which is a Gs-coupled receptor, leads to cAMP-mediated 70 
translocation of aquaporin-2 (AQP2) to the apical plasma membrane. This regulation of 71 
AQP2 water channel localization is crucial to increase urine osmolality and to reduce urine 72 
output in humans (7). Ligand binding of GPCRs also stimulates mechanisms that can lead to 73 
termination of signaling. Impairment of this process can cause diseases as well (8,9). 74 
Desensitization and internalization of GPCRs are regulated by GPCR kinases and β-arrestins 75 
(10,11). Binding of β-arrestin to the desensitized receptor is followed by the internalization, 76 
which decreases the amount of receptors in the plasma membrane. The balance between the 77 
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internalization, degradation, synthesis and recycling determinates essentially the hormone 78 
sensitivity of a tissue (12).  79 
Diabetes insipidus is a syndrome characterized by polyuria, hyposthenuria and 80 
polydipsia. NDI is caused by the impaired effect of AVP in the kidney, although the hormone 81 
secretion is normal. Almost 90% of NDI cases are caused by loss of function mutations of 82 
V2R. More than 200 mutations have been identified worldwide, much of them are missense 83 
mutations, which act by different mechanisms (13). Thus, mutations can be classified into 84 
several groups based on their consequences (14). Class I mutations of the AVPR2 gene lead 85 
to impaired transcription, mRNA processing or translation of the receptor resulting in 86 
truncated and rapidly degraded proteins. Class II mutations lead to the formation of misfolded 87 
full length proteins, which are recognized by the quality control system of the endoplasmic 88 
reticulum (ER), which result in ER retention (15). Thus, class I and II mutations lead to 89 
hormone insensitivity due to decreased number of cell surface receptors. Class III mutants are 90 
another group of missense mutations, which interfere with either G protein coupling or AVP 91 
binding, leading to inappropriate signal transduction without affecting the cell surface 92 
expression of the receptors. Class IV mutants have normal ligand binding but their 93 
intracellular trafficking is altered causing impaired cAMP signal production mostly due to 94 
constitutive β-arrestin dependent internalization into endosomal vesicles (16). 95 
Identification of the altered properties of mutated receptors could help to define 96 
therapeutic strategies for the treatment of NDI patients. Possible therapeutic mechanisms 97 
include direct stimulation of signal generation, bypassing the receptor (14), and different 98 
strategies to rescue the receptor function. The most extensively investigated V2R mutants 99 
belong to the class II mutations, which cause ER retention. Pharmacological chaperons are 100 
chemical ligands, which facilitate the folding of receptors in the ER and rescue them from ER 101 
retention. This mechanism leads to increased plasma membrane expression of otherwise 102 
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functional receptors. Pharmacological chaperones of the V2R can be antagonists (17-21) or 103 
agonists (22,23).  104 
In this study we have identified the N321K mutation of V2R in an NDI patient by 105 
genomic DNA sequencing. Although this mutation was reported previously, the mechanism 106 
of its pathogenic effect has not been identified (6). Here we characterize the pharmacological 107 
and functional properties of this mutant receptor, and based on these findings we propose a 108 
new therapeutic strategy for patients carrying this mutation.  109 
 110 
Materials and methods 111 
 112 
Materials 113 
Molecular biology enzymes were obtained from Fermentas (Burlington, Canada), Stratagene 114 
(La Jolla, CA, USA), and Invitrogen (Carlsbad, CA, USA). Cell culture dishes and plates for 115 
BRET measurements were purchased from Greiner (Kremsmunster, Austria). Lipofectamine 116 
2000 and coelenterazine h were from Invitrogen (Carlsbad, CA, USA). The anti-HA-117 
Alexa488 mouse monoclonal antibody was purchased from Life Technologies (Grand Island, 118 
NY, USA). Unless otherwise stated, all other chemicals and reagents were purchased from 119 
Sigma (St. Louis, MO, USA). The human embryonic kidney (HEK293) cells were from 120 
ATCC (American Type Culture Collection, Manassas, VA, USA). 121 
Mutation analysis 122 
Written informed consent was obtained from a male NDI patient. Genomic DNA was 123 
extracted from peripheral blood leucocytes using DNA isolation kit (Boehringer Mannheim 124 
Corporation, Indianapolis, IN, USA). The AVPR2 gene was amplified with PCR in fractions 125 
using forward primer (5’-ATCACCTCCAGGCCCTCAGA-3’) and reverse primer (5’-126 
ATGGGACGGCAGATGGCAC-3’), as well as forward primer (5’- 127 
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TGATCCTGGCCATGACGCTG-3’) and reverse primer (5’- 128 
AGAGGCAAGACACCCAACAGC-3’). The sizes of the PCR products were determined in 129 
agarose gel and were purified for DNA sequencing. The PCR products were sequenced in 130 
both directions.  131 
Molecular biology 132 
The cDNA of the human arginine vasopressin receptor 2 (Clone ID: AVR0200000, GenBank 133 
Accession Number: ACC#AY242131) was purchased from S&T cDNA Resource Center 134 
(Rolla, MO, USA). The untagged and the HA-tagged V2Rs were subcloned into pcDNA3.1. 135 
For the construction of the super Renilla luciferase (Sluc) tagged V2R, the receptor sequence 136 
was amplified from the cDNA clone and subcloned into a pEYFP-N1 vector (Clontech, 137 
Mountain View, CA, USA) containing the sequence of super Renilla luciferase (24). In order 138 
to create the mVenus-tagged V2R, the amplified receptor was subcloned into a pEYFP-N1 139 
vector containing the sequence of mVenus. Venus contained an A206K mutation holding the 140 
protein in monomeric form (25). β-arrestin2-Rluc was constructed as described previously 141 
(26). The β-arrestin2 was subcloned into a pEYFP vector with replacement of eYFP with 142 
humanized Renilla-luciferase (Promega, Madison,WI). The generation of the MP-YFP was 143 
described previously (27). Mutagenesis was performed using standard site-directed 144 
mutagenesis techniques in order to generate N321K receptor constructs. After verifying the 145 
mutations with dideoxy sequencing, the mutated fragment was exchanged between the wild 146 
type and mutated portion with suitable restriction sites to avoid the generation of unwanted 147 
mutations outside the sequenced regions.  The Epac-BRET sensor was based on the 
T
EPAC
VV
 148 
construct developed and kindly provided by Dr. Kees Jalink (28). For the construction of the 149 
Epac-BRET sensor the mTurquoise part of the 
T
EPAC
VV 
was replaced with Sluc. The Sluc 150 
sequence was amplified with PCR and was subcloned into
  T
EPAC
VV
.  151 
Cell culture and transfection 152 
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Cell culture and transfection protocols were described previoiusly (27). The DNA amounts 153 
were 0.25 μg receptor containing construct/well and 0.25 μg BRET partner containing 154 
construct/well; the amount of Lipofectamine 2000 was 0.5 μl/well.  155 
BRET measurements  156 
BRET measurements were performed as described previously (27). We used either 157 
a Renilla luciferase-fused receptor as the energy donor and an eYFP-tagged protein as the 158 
acceptor or we used intramolecular BRET probe (cAMP measuring Epac-BRET). Dose-159 
response sigmoidal curves were generated using non-linear regression. The statistical analysis 160 
was carried out with two way ANOVA and one way ANOVA with Tukey’s multiple 161 
comparison test. 162 
Confocal microscopy 163 
The cells plated on polylysine-pretreated glass coverslips (3 × 10
5
 cells/35-mm dish) and were 164 
transiently transfected with the HA-tagged receptor constructs (2 μg receptor/well; the amount 165 
of Lipofectamine 2000 was 4 μl/well.). After 24 h, the cells were washed with PBS, and were 166 
fixed with 4% PFA solution for 10 minutes. Cells were washed three times with 10% FBS 167 
containing PBS solution. For the immunostaining the anti-HA-Alexa488 mouse monoclonal 168 
antibodies were diluted to 1:250 in the presence or absence of 1% saponin and the cells were 169 
incubated for 1 h. After washing with 10% FBS-PBS the coverslips were mounted on slides. 170 
The localization and distribution of the targeted probes were analyzed using a Zeiss LSM 510 171 
confocal laser-scanning microscope.  172 
Flow cytometry 173 
The cells were plated on glass coverslips (3 × 10
5
 cells/35-mm dish) were transiently 174 
transfected with the HA-tagged receptor constructs or pcDNA3.1 (2 μg DNA/well; the 175 
amount of Lipofectamine 2000 was 4 μl/well.). The cells were deattached by Versene reagent 176 
treatment and were centrifuged. The cells were suspended in ice cold PBS, and were 177 
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centrifuged on 4 
o
C. The cell pellets were suspended and incubated with diluted (1:100) anti-178 
HA-Alexa488 mouse monoclonal antibodies for 40 minutes on 4 
o
C. After the labeling period 179 
the cells were washed in ice cold PBS. Flow cytometry measurements were performed with 180 
Beckman-Coulter SC. After measuring the fluorescent intensity of the cells, Gmean was 181 
calculated using WinMDI v2.9 (http://facs.scripps.edu). For the relative fluorescent intensity 182 
the background (pcDNA3.1) was subtracted and the data were normalized for the wild type 183 
receptor. Statistical analysis was carried out using two-way ANOVA.  184 
Wire myography 185 
Thoracic aortas from rats were removedand placed into cold Krebs solution containing (in 186 
millimolar) 119 NaCl, 4.7 KCl, 2.5 CaCl2·2H2O, 1.17 MgSO4·7H2O, 20 NaHCO3, 1.18 187 
KH2PO4, 0.027 EDTA, 10.5 glucose. Aortic rings were mounted onto a multichannel 188 
isometric myograph system (Danish Myo Technology, Aarhus, Denmark). The thermostated 189 
(37 °C) organ chambers of the myographs were filled with Krebs solution, which was and 190 
bubbled with carbogen gas (5% CO2 and 95% O2). Resting tension of aortic rings was set to 191 
10 mN and allowed to equilibrate for 30 min. The integrity and functionality of the aortic 192 
ringswere tested by124 mM K
+
 containing KREBS solution (constriction) and after several 193 
washing cycles and waiting period by 10 μMachetylcholine (vasodilation). Recording was 194 
performed with the Powerlab data acquisition system and the LabChart evaluation program 195 
(ADInstruments, Oxford, UK). Vasoconstrictor responses were calculated as percent values of 196 
reference 1µM phenilephrine caused precontraction. Concentration-dependent vasoconstrictor 197 
response curves to agonists were obtained using parallel segments.  198 
 199 
Results 200 
 201 
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The male patient was born in 1984 with polyuria and polydypsia, and NDI was 202 
diagnosed at the age of 18 month since desmopressine (dDAVP), a vasopressin analogue, was 203 
ineffective during the early water deprivation test. Currently his water consumption is 204 
approximately 12 liter/day. Thiazide and amiloride diuretics were ineffective and the water 205 
intake remained unchanged. Clinical laboratory tests of the patient revealed the following 206 
parameters (reference ranges shown in parenthesis): serum sodium 145 mmol/l (136-146), 207 
serum potassium 4.3 mmol/l (3.5-5.0), serum osmolality 282 mOsm/kg (without any 208 
medication, at his usual daily water intake, 275-295). The urine specific gravity was 1003 209 
g/cm
3 
(1002-1030) and the urine osmolality was 72 mOsm/kg (50-1200, depending on fluid 210 
intake).  211 
 The AVPR2 gene was amplified with PCR of the genomic DNA isolated from the 212 
peripheral blood of the patient (see details under “Materials and Methods”) and the mutation 213 
was identified by DNA sequencing. A missense mutation was found in the patient (Fig. 1A)  214 
and this CG substitution results an asparagine lysine change (N321K) in the 7th 215 
transmembrane domain of the V2R (29). No other mutations in the AVPR2 gene were found. 216 
The family anamnesis of the patient suggests that the N321K substitution is not a de novo 217 
mutation, since symptoms of diabetes insipidus were presented in at least 3 generations of his 218 
family (Fig. 1B). However, it was not possible to achieve sequencing of the AVPR2 gene of 219 
other family members. According to the records, the grandmother’s father had suffered from 220 
polydypsia and died at 82 years of age. The grandmother had also suffered from polydypsia 221 
and had a daily water consumption of 6-8 l.  Her 11 months old child died because of 222 
exsiccosis. The mother and sister of the patient are healthy. 223 
We expressed HA-tagged wild type or N321K mutant V2R transiently in HEK293 224 
cells to examine the cellular localization of the receptors. Immunofluorescent staining of the 225 
receptor was performed using anti-HA antibodies tagged with Alexa488 both in 226 
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permeabilized and non-permeabilized cells. Confocal microscopy revealed that the mutant 227 
N321K-V2R is localized in the plasma membrane of the transfected cells very similarly to the 228 
wild-type receptor (Fig. 2A and 2B). Immunostaining of permeabilized cells expressing either 229 
wild type or mutant receptors showed marked intracellular fluorescence. The mock-230 
transfected cells with empty-pcDNA3.1 did not show any fluorescent staining (data not 231 
shown). Taken together, the mutant receptors showed very similar cellular distribution 232 
compared to the wild type receptors. These data show that the N321K-V2R can reach the 233 
plasma membrane of the cells (Fig. 2A-D). Theoretically, the fusion of the mutant receptor 234 
with a tag (HA or fluorescent protein) could alter the trafficking, therefore we used another 235 
approach to determine the localization of the receptors. In order to confirm the plasma 236 
membrane localization of the mutant receptor, we have also used HEK293 cells transiently 237 
expressing fluorescently tagged receptors. The mVenus tagged WT-V2R and N321K-V2R 238 
had similar cellular distribution in living cells assessed by confocal microscopy (data not 239 
shown). We also compared the quantity of the expressed receptors on the surface of 240 
transfected cells performing flow cytometry measurements. HA-tagged WT-V2R and N321K-241 
V2R were transiently transfected in HEK293 cells, and labeled with anti-Ha-Alexa488 242 
antibodies as described in the Materials and Methods. We did not detect any significant 243 
difference in the relative fluorescence intensities (RFI) of the WT (RFI: 1.0) and N321K 244 
receptors (RFI: 0.954±0.05; n=3, p>0.05) on the cell surface indicating that the plasma 245 
membrane expression of the mutant receptor is similar to that of the wild type receptor (data 246 
not shown). 247 
Since these data showed no evidence of the ER retention of transiently expressed 248 
N321K mutant receptors, the function of this mutant receptor was also evaluated. Since V2R 249 
is coupled to Gs, we used bioluminescence resonance energy transfer (BRET) technique to 250 
monitor cAMP generation in living HEK293 cells upon agonist stimulation. The HEK293 251 
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cells were transiently transfected with the Epac-BRET sensor and with either wild type or 252 
N321K-V2R constructs. The experiments were performed 24 hours after the transfection. The 253 
Epac-BRET probe reports when the Epac domain is loaded with cAMP, causing 254 
conformational changes that move away the energy acceptor from the donor, as was shown in 255 
a previous report that presented the corresponding FRET probes (30). Consequently, an 256 
increase in intracellular cAMP level results in a decreased BRET ratio in our measurements. 257 
Fig. 3A shows the real-time evaluation of cAMP levels in living cells expressing either WT-258 
V2R or N321K-V2R. Cells were stimulated at the indicated time with 10 nM AVP (in case of 259 
the wild type receptor, square) or with 1 μM AVP (in case of the mutant receptor, triangle). It 260 
is noteworthy that the basal (before stimulus) BRET ratio is higher in the cells expressing the 261 
N321K-V2R than in the cells expressing the wild type receptor, indicating that the basal 262 
cAMP concentration in the N321K-V2R expressing cells is lower than that of the WT-V2R 263 
expressing cells. Basal cAMP production of wild type V2Rs was already reported in COS7 264 
cells, and it could be blocked with antagonists (31). In agreement with these data, the WT-265 
V2R also possesses basal activity in HEK293 cells, whereas the N321K-V2R lacks the 266 
constitutive activity in our expression system. Although the mutant receptor was able to 267 
stimulate cAMP production upon AVP stimulus with very similar amplitude than that of the 268 
wild type receptor, the kinetics of the activation was different. The cAMP production was 269 
sustained in the cells expressing the WT-V2R, where as it was apparently more transient in 270 
cells expressing the N321K-V2R mutant receptor (Fig. 3A). We also determined the dose-271 
response curve of the mutant and the wild type receptor upon AVP stimulus (Fig. 3B). The 272 
effect of the hormone on the WT-V2R and N321K-V2R expressing HEK293 cells was 273 
calculated as the BRET ratio difference between the ligand and the vehicle treated cells at the 274 
first time points after the treatment. The maximal BRET changes were similar in case of both 275 
receptors, but the potency of the N321K-V2R is dramatically decreased compared to the wild 276 
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type. The pEC50 of AVP for the wild type receptor was 10.46 ± 0.04 M, while that of the 277 
mutant receptor was 6.49 ± 0.07 M.  278 
 The effect of the AVP analogue dDAVP is fundamental both in the diagnosis and the 279 
treatment of diabetes insipidus. Therefore we investigated the effect of dDAVP on cAMP 280 
production in HEK293 cells expressing WT-V2R and N321K-V2R (Fig. 3C). According to 281 
our data the dDAVP has pEC50 of 9.23 ± 0.07 M for WT-V2R, whereas in case of the N321K 282 
mutant receptor we could not measure detectable cAMP production upon dDAVP stimulation. 283 
The inefficiency of dDAVP on N321K-V2R cells is consistent with the clinical data of the 284 
patient who carries this mutation.  285 
Next we examined the internalization properties of the mutant receptor and compared 286 
those with that of the wild type receptor. First, we investigated the β-arrestin2 binding of the 287 
receptors using BRET technique in living cells. Association of the receptor with β-arrestin2 288 
was detected as BRET signal elevation after AVP stimulus indicating the interaction of 289 
mVenus-tagged WT-V2R with Rluc-β-arrestin2. Based on the kinetics of the binding, the 290 
WT-V2R is apparently a class B GPCR (Fig. 4A) (32) Fig. 4B shows the dose-response 291 
curves of β-arrestin2 binding to the receptors after 380 sec stimulation. The pEC50 of β-292 
arrestin2 binding dose-response curve to the wild type receptor was 8.03 ± 0.005 M. 293 
Interestingly, we were not able to detect β-arrestin2 binding in case of the N321K-V2R even 294 
at high, supraphysiological levels of AVP (Fig. 4B, triangle). These data prompted us to 295 
examine the internalization kinetics of the receptors. In this set of experiments the receptors 296 
were tagged with a bioluminescence donor Renilla luciferase (V2R-Sluc), while the energy 297 
acceptor YFP was targeted to plasma membrane by fusing a small tag containing consensus 298 
sequences for myristoylation and palmitoylation (MP-YFP) (27,33). The BRET ratio 299 
monitored the non-specific resonance energy transfer, which is dependent on the distance 300 
between the donor and acceptor. As Fig 4C shows, stimulation of the wild type V2R with1 301 
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μM AVP (square) decreased the BRET ratio, which reflects the altered localization of the 302 
energy donor and the acceptor, indicating the internalization of the cell surface localized 303 
receptors into the endosomal compartments (33). The reduction in BRET ratio between MP-304 
YFP and N321K-V2R-Sluc upon stimulation with 1 μM AVP (triangle) was smaller than that 305 
in case of WT-V2R-Sluc, suggesting that the internalization of N321K-V2R is reduced 306 
compared to the wild type receptor.  307 
Theoretically the functional impairment of theN321K-V2R mutant receptor can be 308 
repaired with an agonist that activates the receptor and has a proper potency in cAMP 309 
production. We tested several commercially available peptides, which are known ligands of 310 
the V2R receptor. Our aim was to find a ligand that activates the mutant receptor initiated 311 
cAMP generation and has a high V2R selectivity over type-1 vasopressin receptor (V1R) in 312 
order to avoid the potential side effects in an in vivo system. Here, we present the results of 313 
cAMP measurements using a selective V2R agonist Val
4
-dDAVP (dVDAVP) (34), a V2R 314 
agonist, but V1R antagonist deamino-Pen
1
,Val
4
-dDAVP (PVDAVP) (35), Lys
8
-VP (LVP) 315 
and Asu
1,6
-AVP (AsuAVP) (36). The dose-response curves were measured in transiently 316 
transfected HEK293 cells using our Epac-based cAMP sensitive BRET probe (Fig. 5). Table 317 
1. shows the calculated EC50 values of the various peptides. The efficacy values of the 318 
dVDAVP, LVP, and AsuAVP peptides were similar to AVP (and dDAVP) after stimulation 319 
of the wild type receptor expressed in HEK293 cells (Fig. 5A, C and D, square). As it was 320 
expected, these peptides had dramatically decreased potency in N321K-V2R expressing cells 321 
(Fig. 5A, B and D, triangle). In case of the PVDAVP the potency is slightly lower than those 322 
of AVP, dVDAVP, LVP, and AsuAVP when the wild type receptor used (Fig. 5B, square), 323 
however PVDAVP did not cause detectable cAMP production of the mutant receptor (Fig. 324 
5B, triangle). From the tested peptides, the agonist dVDAVP had the highest potency (pEC50: 325 
6.3 ± 0.19 M) to activate the mutant receptor, which was comparable to the potency of AVP 326 
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(6.492 ± 0.07  M) to stimulate the cAMP production of this receptor. This finding raised the 327 
possibility that dVDAVP can be used to rescue the function of N321K-V2R. Since the 328 
vasoconstrictor side effect of AVP analogues is a concern during the treatment of NDI, we 329 
have tested the effect of dVDAVP on V1R initiated vasoconstriction of isolated mouse 330 
arteries by wire myography vessels. Fig. 6 shows that increasing concentrations of AVP 331 
caused vasoconstriction through vascular smooth muscle cell, whereas even 10
-5
 M 332 
concentration of dVDAVP was not able to evoke this effect. 333 
 334 
Discussion 335 
In this study we have characterized an N321K missense V2R mutation, which was 336 
identified from a Caucasian male NDI patient. This mutation was already found previously in 337 
another patient, but cellular consequences of the mutation were not examined before (6). The 338 
water deprivation test was carried out in childhood, which clearly diagnosed diabetes 339 
insipidus, moreover the administration of dDAVP did not have any effect on urine 340 
concentration. The familiar anamnesis strongly suggested a genetically inherited mutation, 341 
since the symptoms of diabetes insipidus was presented for at least four generations, which 342 
raised the possibility of an X-linked NDI. Sequencing of the genomic DNA demonstrated a 343 
CG substitution in the AVPR2 gene, which results in an asparagine-lysine change at 344 
position 321 of the V2R. This asparagine is in the NPXXY motif, which is a conserved 345 
sequence in G-protein coupled receptors and assumed to have a role in ligand binding, G-346 
protein coupling and internalization of β-adrenergic receptor (37). Mutation of this asparagine 347 
residue in type I angiotensin receptor (AT1aR) causes markedly reduced G-protein interaction 348 
and generation of second messengers, but has no effect on the internalization kinetics of the 349 
receptor (38). It was clearly shown that mutation of proline 322 in V2R leads to impaired 350 
coupling to Gs protein (4). According to our data, the plasma membrane expression of the 351 
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N321K-V2R was similar to that of the wild type receptor in transient expression systems (Fig. 352 
2). This result suggested that the mutant receptor is delivered to the cell surface and a ER 353 
retention problem is not responsible for the phenotype of this patient. On the other hand, the 354 
stimulation of the mutant receptor with AVP revealed markedly decreased potency and 355 
unchanged efficacy in cAMP production compared to the wild type receptor (Fig. 3B). 356 
Interestingly, we have found that the basal activity of the N321K-V2R was also decreased 357 
compared to WT-V2R (Fig 2A). However, the basal BRET ratio values (before stimulus) of 358 
the unstimulated N321K-V2R in cAMP measurements are identical to the BRET ratios of the 359 
wild type receptor under maximal inhibition with high dose antagonists (data not shown). 360 
Taken together, the mutant receptor has reduced second messenger formation capability both 361 
in the absence and presence of agonists suggesting that the N321K mutation causes impaired 362 
G-protein coupling. However, it is also important that the classification of a receptor mutation 363 
is not always unambiguous. NDI causing R137H-V2R was shown to belong to class IV due to 364 
the constitutive β-arrestin dependent internalization of the receptors (16). Moreover, R137C-365 
V2R and R137L-V2R mutations lead to nephrogenic syndrome of inappropriate dieresis due 366 
to the constitutive activity and β-arrestin dependent internalization. The R137H-V2R has also 367 
impaired G-protein coupling (39) and as it was more recently showed, this mutant has altered 368 
trafficking to the plasma membrane as well (40).   Taken together, these raise the possibility 369 
that one mutation can cause multiple effects on receptor function. 370 
The hormone sensitivity of a tissue is also dependent on the internalization processes 371 
of receptors, which affects the receptor amount in the plasma membrane of the cells. We 372 
characterized and evaluated the internalization properties of the WT-V2R and N321K-V2R in 373 
HEK293 cells using BRET technique to measure the β-arrestin2 binding of the stimulated 374 
receptors. The β-arrestin2 binding dose-response curve of the WT-V2R was right shifted 375 
compared to the cAMP dose-response curve, which reflects the presence of spare receptors in 376 
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the plasma membrane and the enhancement of the generation of second messengers (41,42). 377 
In contrary to the wild type receptor, we could not detect β-arrestin2 binding of the N321K-378 
V2R, therefore we also examined the kinetics of the internalization properties of the receptors. 379 
We used BRET-based approach, where plasma membrane targeted YFP served as indicator of 380 
plasma membrane localization, and we measured the internalization of luciferase tagged 381 
receptors from the cell surface upon stimulation (27). Although this method can also detect 382 
intramembrane movements of the receptor, we have used this method to monitor 383 
internalization of activated receptors, since internalization of the receptor leads to its 384 
divergence form the plasma membrane marker (33). The results showed that the N321K-V2R 385 
had markedly reduced internalization compared to the wild type receptor. It is possible that 386 
the remaining internalization is the consequence of β-arrestin independent processes. It is also 387 
interesting that, in contrast to the angiotensin receptor (37), a mutation in the NPXXY motif 388 
in the V2R leads to impaired β-arrestin binding and internalization. It is also notable that the 389 
reduced internalization does not necessarily mean continuous signaling of the receptor from 390 
the plasma membrane: the transient kinetic of the cAMP signal of the N321K-V2R suggests 391 
that this mutation has no major effects on the desensitization processes (Fig. 2A). Since β-392 
arrestin mediated uncoupling of the GPCR from G-proteins is not the only possible 393 
mechanism of desensitization, i.e. phosphorylation of the receptor by messenger dependent 394 
kinases also can lead to termination of the receptor activation (43).  395 
The clinical diagnosis of the NDI is also based on functional tests. The widely used 396 
tests are the water deprivation test and administration of the dDAVP (44). Since the dDAVP 397 
is an essential compound not only in the diagnostic procedures of NDI, but also in the therapy 398 
of DI, we examined the effect of dDAVP on the mutant N321K receptor. As we mentioned 399 
before, we could not detect any cAMP signal upon dDAVP stimulus (Fig. 3). These results 400 
were consistent with the clinical findings: administration of dDAVP in childhood did not 401 
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exert any improvement in the observed parameters. The dose-response curve of the wild type 402 
receptor showed that the potency of the dDAVP was decreased compared to the AVP.It was 403 
already known that although the dDAVP is a V2R specific agonist it has a lower affinity to 404 
receptor than the AVP (45). Apparently the N321K mutation induces a conformational change 405 
of the V2R resulting in a decreased affinity and/or G-protein coupling, which led to lack of 406 
dDAVP effects on cAMP generation capability in the tested concentrations.  407 
Theoretically, an altered receptor conformation can result decreased potency for a 408 
certain agonist but potency of other agonists can be affected differently. An agonist, which 409 
could activate the mutant receptor despite of the conformational change, can be the causal 410 
therapy in case of a mutation, such as N321K. In order to find such a compound, we tested 411 
several agonists with high affinity to the V2R (Fig. 5 and Table 1). Statistical analysis showed 412 
that  the effects of the agonists were significant (p<0,0001) on the pEC50 values using two 413 
way ANOVA. The wild type receptor had similar potency for LVP, dVDAVP and AsuAVP. 414 
The PVDAVP had the lowest EC50  in case of wild type V2R, and we could not detect any 415 
cAMP signal with the N321K-V2R, although this peptide was thought to be beneficial for a 416 
potential therapy because of the V1R antagonistic effect (35). The dVDAVP had the highest 417 
potency on the N321K-V2R, moreover the N321K mutation had the reduced effect in case of 418 
this compound: the difference between the mutant and the wild type receptor in the potency 419 
was one order of magnitude less than with other agonist (ΔpEC50 (M) of dVDAVP is 3.71, for 420 
AsuAVP and LVP are 4.62 and 4.56 respectively). Using one way ANOVA statistical 421 
analysis with Tukey’ multiple comparison test, the differences between the ΔpEC50 values of 422 
the dVDAVP and the other agonists (AsuAVP and LVP) were significant (p<0,005). The 423 
consequence of the N321K missense mutation is misfolding, resulting in a conformation with 424 
altered agonist sensitivity, which is more suitable for stimulation by dVDAVP than for other 425 
agonists. Fortunately, as was demonstrated earlier, the most effective AVP analogue 426 
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dVDAVP among the tested compounds is a selective V2R agonist (34). A potential high dose 427 
agonist treatment could be limited because of the cross reaction of the compound on the 428 
vascular V1Rs. The V1aR is expressed in various tissues such as in the walls of vascular 429 
vessels (46). Although the physiological concentration of AVP is lower than the concentration 430 
that exerts vasoconstriction, a high dose of vasopressin receptor agonist in the treatment of DI 431 
could provoke side effects (vasoconstriction, blood pressure elevation) through this system. 432 
The consequence of the agonist activity on V1R could be hypertension and according to 433 
studies in septic shocka decreased perfusion of the heart, kidney and intestines (47). In this 434 
present study we examined whether the high dose of dVDAVP, which is able to generate 435 
cAMP signal through the activation of N321K-V2R could promote vasoconstriction in 436 
peripheral arterioles. As Fig. 6 shows, we could not detect any constriction even at 10 µM 437 
final dVDAVP concentration. This result suggests that an appropriate (moderately high) dose 438 
treatment could have beneficial effects on the NDI symptoms including polyuria and 439 
polydipsia without the unsafe side effect vasoconstriction.  440 
Although dVDAVP did not become an alternative drug of dDAVP in the clinical 441 
therapy of NDI over the years, but several studies are in the literature about the clinical use of 442 
dVDAVP. Czakó et al showed in a clinical trial that dVDAVP was not only more effective 443 
than dDAVP in patients with central DI, but that it also had a short term, moderate 444 
antidiuretic effect in patients with ‘ADH resistant diabetes insipidus’(48). The dVDAVP had 445 
three times longer antidiuretic effect in central DI than dDAVP after intravenous injection. It 446 
has also been shown that an intranasal use of dVDAVP was also similarly effective as 447 
dDAVP in these patients. 448 
In this study we demonstrated that the disease causing N321K mutation of the V2R 449 
does not lead to ER retention and the N321K-V2R is present in the plasma membrane of 450 
HEK293 cells. The mutant receptor has an unchanged efficacy but dramatically decreased 451 
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potency for AVP. The N321K-V2R mutation leads to impaired internalization, most likely 452 
due the lack of β-arrestin binding upon stimulation with agonist concentrations which 453 
generate maximal cAMP signal. The N321K-V2R is biased among different ligands, as the 454 
misfolding and the conformational change due to the mutation causes different sensitivities of 455 
agonists. According to our data, the function of the mutant receptor can be rescued with 456 
administration of V2R receptor agonist dVDAVP, which had no detectable side effects on 457 
V1R in the effective cAMP signal causing concentration. Our in vivo experiments propose the 458 
possibility that appropriate dosage of dVDAVP can rescue the function of the N321K-V2Rin 459 
a NDI patient with no significant side effect on V1R.  Based on these findings a therapeutic 460 
strategy can be formed for patients with N321K mutation in the V2R. 461 
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 630 
 631 
Figure legends 632 
Figure 1: The results of DNA sequencing and the familiar anamnesis. (A) The genomic 633 
DNA was isolated from peripheral blood. After PCR amplification the AVPR2 gene was 634 
sequenced. The chromatogram shows the results of the sequencing in the patient and in a 635 
healthy control. (B) Familiar anamnesis of the patient. Filled mark indicates polydipsia-636 
polyuria syndrome in the male (squares) and female (circles) members of the family. The 637 
scored marks indicate deceased family members.  638 
 639 
Figure 2: Examination of the cell surface expression of the N321K-V2R. 640 
Immunofluorescence microscopy analysis of HEK293 cells transiently expressing wild type 641 
(A and C) or N321K (B and D) HA-tagged V2R. The samples were stained with anti-HA-642 
Alexa488 mouse monoclonal antibodies under permeabilized (C and D) and non-643 
permeabilized (A and B) conditions. Scale bars represent 10 µm.  644 
 645 
Figure 3: Measurement of the cAMP signal upon AVP and dDAVP stimuli. HEK293 646 
cells were transiently transfected with the wild type or the N321K-V2R and the Epac-BRET 647 
sensor. After 24 h, the BRET measurements were implemented. (A) The cells were stimulated 648 
with 10 nM AVP in case of the wild type (square) and with 1 μM AVP in case of the mutant 649 
receptor (triangle) at the indicated time. Dose response curve of AVP (B) and dDAVP (C). 650 
The effect of the hormone on the WT-V2R and N321K-V2R expressing HEK293 cells was 651 
calculated as the BRET ratio difference between the ligand (stim) and the vehicle (nstim) 652 
treated cells at the first time points after the treatment. Mean values ± S.E. are shown (n = 3). 653 
 654 
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Figure 4: Examination of the internalization and β-arrestin binding properties of 655 
N321K-V2R. HEK293 cells were transiently transfected with the plasmids of the indicated 656 
BRET partners and after 24h, the cells were exposed to AVP or vehicle. (A-B) β-arrestin 657 
binding was measured with the transfection of wild type- or N321K-V2R-mVenus and β-658 
arrestin-Rluc plasmids. (A) Cells were exposed either to 1µM AVP (square) or vehicle 659 
(dashed line) at the indicated time points. (B) Dose response curve of β-arrestin binding of 660 
AVP. The effect of the hormone on cells was calculated as the BRET ratio difference between 661 
the ligand (stim) and the vehicle (nstim) treated cells. (C) Internalization kinetics was 662 
measured with the transfection of wild type- or N321K-V2R-Sluc and MP-YFP plasmids. 663 
Cells were exposed either to 1µM AVP or vehicle at the indicated time points.  Mean values ± 664 
S.E. are shown (n = 3). 665 
 666 
Figure 5: Measurement of the cAMP signal upon different agonist stimuli. HEK293 cells 667 
were transiently transfected with the wild type or the N321K-V2R and the Epac-BRET 668 
sensor. After 24 h, the BRET measurements were implemented. Dose response curves of 669 
dVDAVP (A), PVDAVP (B), LVP (C) and AsuAVP (D). The effect of the hormones on the 670 
WT-V2R and N321K-V2R expressing HEK293 cells were calculated as the BRET ratio 671 
difference between the ligand (stim) and the vehicle (nstim) treated cells at the first time 672 
points after the treatment. Mean values ± S.E. are shown (n = 3). 673 
 674 
Figure 6: Effects of AVP and dVDAVP on vasoconstriction of mouse arterioles. Isolated 675 
mouse arterioles were exposed to increasing concentrations of AVP (square) or dVDAVP 676 
(triangle). The values of the vasoconstrictor responses were calculated as percent values of 677 
reference 1µM phenilephrin caused precontraction. The values are average of 3 independent 678 
experiments. Mean values ± SEM are shown (n = 3). 679 
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Table 1. 694 
pEC50 
(M) 
WT N321K 
AVP 10.46±0.04 6.492±0.07 
dDAVP 9.229±0.07  
dVDAVP 10.02±0.11 6.30±0.05 
AsuAVP 10.56±0.04 5.94±0.02 
LVP 10.08±0.02 5.52±0.13 
PVDAVP 8.75±0.01  
 695 
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